authors received honoraria from Bayer. However, withholding this information in the publication of results [3, 4] and declaring that there was no conflict of interest [3] is misleading.
Most regretfully, the response by Chiasson et al. to our For Debate article [1] has not clarified any of the critical points we made. In contrast, it confirms most of our objections with regard to the methodology and the results of the STOP-NIDDM Trial [2, 3, 4, 5] . Chiasson et al. write: "...for patients with risk of cardiovascular events, the number of patients at risk with acarbose treatment is smaller than the number of patients at risk in the placebo group. This is due to the fact that premature discontinuation of study medication was more frequent in the acarbose group". What this means is that patients who discontinued the medication, mostly due to acarbose-induced side effects, were not included in the at-risk population. Even if some of the patients were only examined at the end of the trial, they should still have been included in the atrisk population for the life table analysis, but they were not. Hence, from the total group of 714 patients randomised to acarbose, 55 had no follow-up examination at all, and up to 211 patients who discontinued their participation in the trial early were not followedup regularly every 3 months like the rest of the patients, which is not in accordance with the intentionto-treat evaluation principle. Therefore, the number of patients at risk is much smaller in the acarbose group, which very well explains the difference of 17 patients with documented cardiovascular events between the groups.
Also, despite published correspondence on this issue [5] , Chiasson et al. again fail to comment on the possible case of data suppression. We asked for an explanation of the fact that 61 patients were excluded from the efficacy analysis because of no post-randomisation data, but data on cardiovascular events in these patients have been published by the sponsor of the trial on the Internet [1, 5] . In addition, the authors report [4] adverse events in all 1429 patients (Tables 2  and 4 ). We do not understand how the authors were able to assess adverse events in all randomised patients during the course of the trial, but had no chance to document any post-randomisation data on cardiovascular events in at least 61 patients [3] .
With regard to the predefinition of cardiovascular endpoints, we can only comment on published information [2, 3] because we have no access to unpublished "on file" protocols of this study. Clearly, endpoints have been changed from the publication of the study protocol [2] to the publication of the study results [3] . In the published protocol [2] secondary endpoints are myocardial infarction, cerebrovascular accident and congestive heart failure; in the publication of the results [3] , three secondary endpoints were added: peripheral vascular disease, angina and revascularisation procedures. The authors report 17 nonpredefined secondary endpoint events in the acarbose group and 33 in the placebo group [3] . Chiasson et al. fail to inform us why these endpoints were subsequently added, or omitted in the publication of the study protocol [2] , and whether the statistical comparison of the published predefined endpoints yields significant results. Most surprisingly, mortality, which was twice as high in the acarbose group as in the placebo group [4] , was not regarded as a study endpoint.
In the published protocol [2] , the final close-out visit was defined after a 3-month washout period on placebo. A life table analysis of the primary endpoint results including this final examination has never been published, nor has any amendment to the protocol explaining why the method of evaluation was changed.
In addition, Chiasson et al. do not explain the rationale behind assessing the risk for the development of hypertension in patients who are already hypertensive. 
